{"id":2119,"date":"2025-03-17T17:57:03","date_gmt":"2025-03-17T14:57:03","guid":{"rendered":"https:\/\/systempharm.com.ua\/?p=2119"},"modified":"2025-03-17T17:57:03","modified_gmt":"2025-03-17T14:57:03","slug":"formation-of-genitourinary-disorders-in-women","status":"publish","type":"post","link":"https:\/\/systempharm.com.ua\/en\/formation-of-genitourinary-disorders-in-women\/","title":{"rendered":"Formation of genitourinary disorders in women"},"content":{"rendered":"<p>Formation of genitourinary disorders in women at the stage of menopausal transition. Research.<\/p>\n<p>At the stage of menopausal transition, caused by hormonal and reproductive changes, a spectrum of<br \/>\ngenitourinary disorders is formed 3-5 years earlier than in the past.<\/p>\n<p>Purpose of the study: to evaluate the effectiveness of local use of suppositories with anti-inflammatory and regenerative effects, which contain tea tree oil, aloe extract and hyaluronic acid, the drug Regianorm, to eliminate the manifestations of vulvovaginal atrophy in women at the stage of menopausal transition.<\/p>\n<p>Materials and methods. A gynecological, urological, sexological examination was conducted on 56 women aged 44 to 46<br \/>\nyears at the final stage of menopausal transition with complaints of burning in the vestibule and vagina, impaired<br \/>\nlubrication, dyspareunia and discomfort during urination.<\/p>\n<p>Results.<br \/>\nAmong the examined women:<br \/>\n&#8211; the highest degree of vulvovaginal atrophy was established in 4 (7.1%) patients,<br \/>\n&#8211; manifested \u2013 in 8 (14.3%),<br \/>\n&#8211; moderate \u2013 in 34 (60.7%),<br \/>\n&#8211; weak \u2013 in 10 (17.9%).<\/p>\n<p>&#8211; In 12 (21.4%) women with high<br \/>\nand manifest degrees of vulvovaginal atrophy,<br \/>\n&#8211; as well as in 24 (42.8%) with moderate atrophy, dyspareunia was formed against the background of impaired<br \/>\nlubricating, which complicated and made sexual intercourse impossible.<\/p>\n<p>The patients&#8217; bad mood, dissatisfaction with themselves negatively affected relationships with their partners, forming<br \/>\nsexual disharmony.<\/p>\n<p>Patients with moderate and mild vulvovaginal atrophy (44 individuals \u2013 78.6%) also reported decreased sexual desire and arousal, difficulty achieving orgasm and obtaining pleasure.<\/p>\n<p>Conclusions.<br \/>\nThe conducted studies demonstrated that the reduction of vulvovaginal atrophy in 42 (75.0%) women at the stage of menopausal transition using suppositories containing tea tree essential oil, aloe vera, and hyaluronic acid with delicate regenerative, restorative, and anti-inflammatory effects,<br \/>\ncaused by the combination of tea tree oil, aloe extract, and hyaluronic acid, contributes to improved lubrication, elimination of dyspareunia, restoration of sexual relations in 48 (85.7%) couples, and improved quality of life and self-esteem in all subjects.<\/p>\n<h3><a href=\"https:\/\/systempharm.com.ua\/wp-content\/uploads\/2025\/03\/Sistemfarm.pdf\" target=\"_blank\" rel=\"noopener\">The full version of the study is in the file<\/a><\/h3>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Formation of genitourinary disorders in women at the stage of menopausal transition. Research. At the stage of menopausal transition, caused by hormonal and reproductive changes, a spectrum of genitourinary disorders is formed 3-5 years earlier than in the past. Purpose of the study: to evaluate the effectiveness of local use of suppositories with anti-inflammatory and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2117,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/posts\/2119"}],"collection":[{"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/comments?post=2119"}],"version-history":[{"count":4,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/posts\/2119\/revisions"}],"predecessor-version":[{"id":2123,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/posts\/2119\/revisions\/2123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/media\/2117"}],"wp:attachment":[{"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/media?parent=2119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/categories?post=2119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/systempharm.com.ua\/en\/wp-json\/wp\/v2\/tags?post=2119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}